{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:00:07Z","timestamp":1782990007734,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s12185-020-02855-4","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T06:35:31Z","timestamp":1584081331000},"page":"243-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation"],"prefix":"10.1007","volume":"112","author":[{"given":"Michiko","family":"Kida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Chishaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Kuraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"key":"2855_CR1","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbmt.2019.01.011","volume":"25","author":"S Yuda","year":"2019","unstructured":"Yuda S, Fuji S, Onishi A, Tanaka T, Inatomo Y, Kurosawa S, et al. Extramedullary relapse of acute myelogenous leukemia after allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:1152\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2855_CR2","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12185-009-0385-3","volume":"90","author":"T Ando","year":"2009","unstructured":"Ando T, Mitani N, Matusi K, Yamashita K, Nomiyama J, Tsuru M, et al. Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t (8;21) and CD56-positivity. Int J Hematol. 2009;90:374\u20137.","journal-title":"Int J Hematol"},{"key":"2855_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.blre.2016.04.001","volume":"30","author":"M Solh","year":"2016","unstructured":"Solh M, Solomon S, Morris L, Holland K, Bashey A. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30:333\u20139.","journal-title":"Blood Rev"},{"key":"2855_CR4","first-page":"1380","volume":"90","author":"JH Lee","year":"2005","unstructured":"Lee JH, Choi SJ, Seol M, Lee YS, Ryu SG, Park CJ, et al. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. Haematologica. 2005;90:1380\u20138.","journal-title":"Haematologica"},{"key":"2855_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa074306","volume":"358","author":"RF Schlenk","year":"2008","unstructured":"Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioqlu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909\u201328.","journal-title":"N Engl J Med"},{"key":"2855_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2855_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","volume":"30","author":"S Brunet","year":"2012","unstructured":"Brunet S, Labopin M, Esteve J, Cornelissen J, Socie G, Iori A, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30:735\u201341.","journal-title":"J Clin Oncol"},{"key":"2855_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/ejh.12841","volume":"98","author":"AT Fathi","year":"2017","unstructured":"Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Eur J Haemal. 2017;98:330\u20136.","journal-title":"Eur J Haemal"},{"key":"2855_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12185-019-02727-6","volume":"110","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Usuki K, Matsue K, Ohno H, Sakura T, Imanaka R, et al. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study. Int J Hematol. 2019;110:665\u201374.","journal-title":"Int J Hematol"},{"key":"2855_CR10","first-page":"3074","volume":"93","author":"H Kiyoi","year":"1999","unstructured":"Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutation in acute myeloid leukemia. Blood. 1999;93:3074\u201380.","journal-title":"Blood"},{"key":"2855_CR11","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.3109\/10428194.2016.1153087","volume":"57","author":"C Yamamoto","year":"2016","unstructured":"Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, et al. Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. Leuk Lymphoma. 2016;57:2541\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2855_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S1525-1578(10)60458-8","volume":"5","author":"KM Murphy","year":"2003","unstructured":"Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5:96\u2013102.","journal-title":"J Mol Diagn"},{"key":"2855_CR13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.bbmt.2012.05.010","volume":"18","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Ando T, Ogawa H. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transplant. 2012;18:1800\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2855_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3324\/haematol.2012.073189","volume":"98","author":"AC Harris","year":"2013","unstructured":"Harris AC, Kitko CL, Couriel DR, Braun TM, Choi SW, Magenau J, et al. Extramedullary relapse of acute myeloid leukemia following allogeneic stem cell transplantation: incidence, risk factors and outcomes. Haematologica. 2013;98:179\u201384.","journal-title":"Haematologica"},{"key":"2855_CR15","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/bmt.2011.163","volume":"47","author":"S Yoshihara","year":"2012","unstructured":"Yoshihara S, Ikegame K, Kaida K, Taniguchi K, Kato R, Inoue T, et al. Incidence of extramedullary relapse after haploidentical SCT for advanced AML\/myelodysplastic syndrome. Bone Marrow Transplant. 2012;47:669\u201376.","journal-title":"Bone Marrow Transplant"},{"key":"2855_CR16","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1182\/blood-2006-09-047225","volume":"109","author":"M Bornhauser","year":"2007","unstructured":"Bornhauser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C. Improved outcome after stem-cell transplantation in FLT3\/ITD-positive AML. Blood. 2007;109:2264\u20135.","journal-title":"Blood"},{"key":"2855_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1620\/tjem.220.121","volume":"220","author":"T Ando","year":"2010","unstructured":"Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, et al. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med. 2010;220:121\u20136.","journal-title":"Tohoku J Exp Med"},{"key":"2855_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Bloomfield CD, Thiede C, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"2855_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR, et al. Selective inhibition of FLT3 by gilteritinib in relapsed\/refractory acute myeloid leukemia: a multicenter, first-in-human, open-label, phase 1\/2 study. Lancet Oncol. 2017;18:1061\u201375.","journal-title":"Lancet Oncol"},{"key":"2855_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.2217\/fon-2017-0582","volume":"14","author":"CM Gorcea","year":"2018","unstructured":"Gorcea CM, Burthem J, Tholouli E. ASP2215 in the treatment of relapsed\/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial. Fut Oncol. 2018;14:1995\u20132004.","journal-title":"Fut Oncol"},{"key":"2855_CR21","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Naubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728\u201340.","journal-title":"N Engl J Med"},{"key":"2855_CR22","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","volume":"113","author":"S Metzelder","year":"2009","unstructured":"Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichier S, Chaturvedi A, et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood. 2009;113:6567\u201371.","journal-title":"Blood"},{"key":"2855_CR23","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.leukres.2010.10.025","volume":"35","author":"F Sora","year":"2011","unstructured":"Sora F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Leurenti L, et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3\/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. Leuk Res. 2011;35:422\u20133.","journal-title":"Leuk Res"},{"key":"2855_CR24","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2011.07.011","volume":"17","author":"M Sharma","year":"2011","unstructured":"Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011;17:1874\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2855_CR25","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1007\/s00277-015-2461-5","volume":"94","author":"A Tschan-Plessl","year":"2015","unstructured":"Tschan-Plessl A, Halter JP, Heim D, Medinger M, Passweg JR, Gerull S. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Ann Hematol. 2015;94:1899\u2013905.","journal-title":"Ann Hematol"},{"key":"2855_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.leukres.2008.04.017","volume":"33","author":"NN Safaian","year":"2009","unstructured":"Safaian NN, Czibere A, Bruns I, Fenk R, Reinnecke P, Dienst A, et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res. 2009;33:348\u201350.","journal-title":"Leuk Res"},{"key":"2855_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/ajh.21511","volume":"84","author":"SH Lee","year":"2009","unstructured":"Lee SH, Paietta E, Racevskis J, Wiernik PH. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol. 2009;84:701\u20132.","journal-title":"Am J Hematol"},{"key":"2855_CR28","first-page":"1932","volume":"53","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kawakami T, Sato H, Onoda T, Kanno M, Mitsui T, et al. Successful treatment with sorafenib for primary refractory acute monoblastic leukemia with FLT3-ITD. Rinsho Ketsueki. 2012;53:1932\u20136.","journal-title":"Rinsho Ketsueki"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-020-02855-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02855-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:57:46Z","timestamp":1615597066000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-020-02855-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2855"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02855-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}